Serine protease inhibitor Kazal-type 1 (SPINK1) mRNA (SPINK1 mRNA)

Serine protease inhibitor Kazal-type 1 (SPINK1) mRNA is the transcript encoding a potent protease inhibitor originally identified in the pancreas, where it protects against autodigestion by inhibiting prematurely activated trypsin [1, 2]. Beyond its physiological role, SPINK1 mRNA is significantly overexpressed in approximately 10-15% of prostate cancers, particularly those lacking ETS rearrangements, where it acts as an autocrine and paracrine factor to drive cell proliferation, invasion, and epithelial-mesenchymal transition [3, 5]. In these oncogenic contexts, SPINK1 interacts with the epidermal growth factor receptor (EGFR) signaling pathway to promote tumor growth [4]. Therapeutic strategies targeting SPINK1 mRNA involve the use of RNA interference (siRNA) or antisense oligonucleotides (ASOs) to silence its expression, thereby inhibiting the aggressive phenotype of SPINK1-positive tumors [3]. Additionally, mutations in the SPINK1 gene are linked to chronic pancreatitis, highlighting its critical role in maintaining pancreatic homeostasis [2]. The mRNA itself serves as a specific target for nucleic acid-based therapies aimed at reducing the levels of the pro-tumorigenic protein in patients with SPINK1-overexpressing cancers [3]. Monitoring SPINK1 mRNA levels can also serve as a diagnostic and prognostic biomarker in various malignancies, including pancreatic and hepatocellular carcinomas [1, 5].

Other names

Pancreatic secretory trypsin inhibitor mRNAPSTI mRNATumor-associated trypsin inhibitor mRNATATI mRNASpink1 transcript

RNA interference (siRNA) and antisense-mediated mRNA degradation (ASO) to reduce protein translation.